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Abstract: Introduction: Pharmacovigilance may detect safety issues after marketing of medications,
and this can result in regulatory action such as direct healthcare professional communications (DHPC).
DHPC can be effective in changing prescribing behaviour, however the extent to which prescribers
vary in their response to DHPC is unknown. This study aims to explore changes in prescribing and
prescribing variation among general practitioner (GP) practices following a DHPC on the safety of
mirabegron, a medication to treat overactive bladder (OAB). Methods: This is an interrupted time
series study of English GP practices from 2014–2017. National Health Service (NHS) Digital provided
monthly statistics on aggregate practice-level prescribing and practice characteristics (practice staff
and registered patient profiles, Quality and Outcomes Framework indicators, and deprivation of
the practice area). The primary outcome was monthly mirabegron prescriptions as a percentage of
all OAB drug prescriptions and we assessed the change following a DHPC issued by the European
Medicines Agency in September 2015. The DHPC stated mirabegron use was contraindicated with
severe uncontrolled hypertension and cautioned with hypertension. Variation between practices in
mirabegron prescribing before and after the DHPC was assessed using the systematic component of
variation (SCV). Multilevel segmented regression with random effects quantified the change in level
and trend of prescribing after the DHPC. Practice characteristics were assessed for their association
with a reduction in prescribing following the DHPC. Results: This study included 7408 practices.
During September 2015, 88.9% of practices prescribed mirabegron and mirabegron comprised a
mean of 8.2% (SD 6.8) of OAB prescriptions. Variation between practices was classified as very high
and the median SCV did not change significantly (p = 0.11) in the six months after the September
2015 DHPC (12.4) compared to before (11.6). Before the DHPC, the share of mirabegron over all
OAB drug prescriptions increased by 0.294 (95% confidence interval (CI), 0.287, 0.301) percentage
points per month. There was no significant change in the month immediately after the DHPC
(−0.023, 95% CI −0.105 to 0.058), however there was a significant reduction in trend (−0.036, 95% CI
−0.049 to −0.023). Higher numbers of registered patients, patients aged ≥65 years, and practice
area deprivation were associated with having a significant decrease in level and slope of mirabegron
prescribing post-DHPC. Conclusion: Variation in mirabegron prescribing was high over the study
period and did not change substantively following the DHPC. There was no immediate prescribing
change post-DHPC, although the monthly growth did slow. Knowledge of the degree of variation
in and determinants of response to safety communications may allow those that do not change
prescribing habits to be provided with additional support.
Keywords: pharmacovigilance; drug safety; segmented regression; interrupted time series; variation
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1. Introduction
When medicines are first launched, evidence of drug efficacy and safety may be incomplete,
and for approximately 10% of drugs, information about serious risks associated with the drug do
not become known until after being released onto the market [1]. The pre-marketing phase based
on randomised controlled trials generally involves healthier participants than the general patient
population, relatively short durations of follow-up, and sample sizes which only power to detect a
difference in the primary efficacy outcome. Post-marketing pharmacovigilance is necessary to monitor
benefits and risks based on real-world use. Emerging safety issues identified in post-marketing
monitoring may require regulatory action to maintain a favourable risk-benefit ratio. This can involve
a change in the terms of a product licence, a direct healthcare professional communication (DHPC)
from medicine regulators to healthcare professionals warning of a new adverse effect, caution, or
contraindication, or withdrawal of a drug from the market.
An example of a drug recently subject to a Europe-wide DHPC is mirabegron, licensed for the
treatment of overactive bladder (OAB) by the European Medicines Agency (EMA) in December 2012 [2].
It is a beta-3 adrenoreceptor agonist and is the first treatment for OAB with this therapeutic target.
Other pharmacological treatment options for OAB such as oxybutynin are antimuscarinic drugs, which
carry a risk of anticholinergic adverse effects due to their mechanism of action, such as dry mouth,
dizziness, constipation, and cognitive impairment [3]. Mirabegron, as a new active substance, is subject
to additional monitoring post-marketing, generally for a period of five years under EMA rules. In July
2015, a review of safety data by the EMA found an increased risk of severe hypertension associated
with mirabegron, and cerebrovascular and cardiovascular events such as stroke linked to mirabegron
had been reported. The EMA deemed that this required active dissemination regarding the change
of use of mirabegron. A DHPC letter was sent to healthcare professionals in September 2015 by
European medicine regulators to inform them that mirabegron was contraindicated in patients with
severe uncontrolled hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure
≥110 mmHg, or both) [4]. The product license was also amended to caution prescribing where systolic
or diastolic blood pressure is ≥160 mmHg or diastolic blood pressure ≥100 mmHg respectively.
DHPCs have been shown to be effective in changing prescribing behaviour. The impact of these
has been evaluated for a wide range of therapeutics, including selective serotonin reuptake inhibitors,
antipsychotics and oral contraceptives [5–7], and DHPCs for safety issues with a risk of death and/or
disability may have a greater impact on prescribing [8]. However, the extent to which prescribers vary
in their response to regulatory safety communications is unknown. An understanding of the degree of
variation in and determinants of uptake of DHPCs may allow groups that do not change prescribing
to be supported with specific interventions.
This study aims to explore changes in prescribing in general practices in England following a
DHPC regarding the safety of mirabegron.
The objectives were:
To quantify variation between general practitioner (GP) practices in rates of mirabegron
prescribing before and after regulatory safety communication
To determine the effect of this safety warning on the level and trend of mirabegron prescribing
among general practices in England
To quantify variation between GP practices in response to the regulatory safety communication, and
To identify GP practice factors that explain variations in the response to the regulatory
safety communication.
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2. Methods
2.1. Study Design, Setting and Participants
The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement
has been used in the reporting of this research [9]. This study utilises an interrupted time series design,
the strongest quasi-experimental design to assess the effect of policy or regulatory interventions [10].
The setting is English general practice and includes all GP practices in England using prescribing
data available from the National Health Service (NHS) Digital platform. This provides monthly
statistics of prescribing of different medicines aggregated at the level of GP practices for all practices
in England. The study period was January 2014 to March 2017. Atypical practices were excluded,
i.e., those with <750 registered patients or <500 patients registered per full time equivalent (FTE) GP,
or if there are >5000 registered patients per FTE GP. This is consistent with previous studies utilising
administrative GP practice data from the same source [11]. In addition, practices with fewer than
100 prescriptions per month during the 12 months either before or after the DHPC (i.e., from August
2014 to October 2016) were excluded, to ensure that included practices contributed sufficient data in
the immediate period before and after the DHPC.
2.2. Variables
The primary outcome was prescriptions for mirabegron as a percentage of all prescriptions for
drugs to treat OAB.
Characteristics of GP practices which may relate to prescribing include the number of FTE GPs
in each practice, the age and sex distribution of GPs, and whether the practice has any registrar GPs
(i.e., qualified doctors undertaking specialist training in general practice) [11]. Indicators of quality of
care through the Quality and Outcomes Framework (QOF) are available for each practice, including
the overall score, as well as indicators relating to specific conditions such as cardiovascular disease.
Information is also provided on the practice list size (i.e., the number of patients registered to each
practice), and the age and sex distribution of registered patients. Lastly, although no other practice-level
patient characteristics are available, the Index of Multiple Deprivation (IMD) of the geographic area a
practice is located in was used.
2.3. Data Sources/Measurement
Monthly prescribing data relating to mirabegron, OAB drugs and all prescription items were
downloaded from the NHS Digital website for the study period. Prescribed products are coded
based on their British National Formulary (BNF) classification, and mirabegron (0704020AE) and
OAB drug prescribing (070402) were defined using this coding. All drugs listed in BNF section 7.4.2
(Urinary frequency, enuresis, and incontinence) were considered as OAB drugs (see Supplementary
Table S1). The number of prescriptions for each product that was dispensed in the specified month is
captured in this data. The data relates to NHS prescriptions issued by general practices in England
and dispensed in any community pharmacy in the United Kingdom (UK). Prescriptions may be
issued by any prescribing staff within practices, including GPs, nurses, and pharmacists and private
prescriptions are not included.
Baseline GP practice workforce and registered patient data (i.e., from 2014) for included practices
were downloaded from the NHS Digital website and were summarised at the practice level. In addition,
QOF indicators were obtained for 2014 and 2015 for overall score and indicators of hypertension and
dementia prevalence (which could plausibly explain variation in prescribing of mirabegron and
other antimuscarinic OAB drugs, respectively). For deprivation, the IMD for 2015 is provided for
geographic areas (lower-level super output areas or LSOA) by the Department for Communities and
Local Government. The index captures the following dimensions of deprivation: income, employment,
education, health, crime, access to housing and services, and living environment. Practices were
assigned the IMD decile of the LSOA they were located in based on their postcode.
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As this study used publicly available data aggregated at the GP practice-level, ethical approval
was not required.
2.4. Analysis
Descriptive statistics are presented for practices which met inclusion criteria. Prescribing patterns
were summarised for each month, including the proportion of practices prescribing any mirabegron,
mirabegron and OAB prescriptions, and mirabegron as a percentage of OAB prescriptions. We graphed
monthly percentiles of mirabegron’s percentage share of OAB prescriptions to describe variation over
time. Between-practice variation in prescribing before and after the September 2015 DHPC was
assessed using the systematic component of variation (SCV) based on practices between the 5–95th
percentiles of mirabegron prescribing. The SCV estimates the true or non-random part of total variation
and performs well as a measure of variation [12–14]. Variation is classified as either low (less than
3), moderate (between 3 and 5.4), high (between 5.4 and 10), or very high (greater than 10) [12].
In particular, we examined variation in the six months before and after the DHPC and assessed
whether the median SCV differed significantly before and after, using the Wilcoxon ranked sum test.
Standardised prescribing ratios (mirabegron’s percentage share of all OAB prescriptions in a practice
each month divided by the percentage share across all practices each month) were calculated and
plotted by month to visually inspect variation. Ratios >1 indicate a higher percentage than average.
To examine variation relative to the month of the DHPC, we calculated a rolling average of practices’
mean percentage of mirabegron prescriptions over the previous six months, expressed as a ratio of
the practice percentage in September 2015. Deciles and 1st to 9th bottom and top percentiles of these
ratios were graphed to assess whether the distribution of practices differed before and after the DHPC.
This approach has been used previously to assess variation following guidance being issued regarding
tamoxifen use [15].
Interrupted time series studies of policy interventions can be analysed using segmented regression,
allowing for the change in level and trend of an outcome following an intervention to be evaluated [10].
A multilevel segmented regression model was fitted to account for repeated monthly observations
clustered within practices, with monthly mirabegron percentage as the outcome. Random effects (to
allow slope and intercept parameters to vary by practice) were included to determine the change in level
and trend of prescribing after the DHPC, using an unstructured covariance matrix. Appropriateness of
inclusion of random effects was assessed using the likelihood ratio test for the following parameters:
level of prescribing pre-safety warning in August 2015 (intercept), the change in level of prescribing
immediately post-warning in October 2015 (change in intercept), the monthly trend in prescribing
pre-warning (slope), and the change in the monthly trend post-warning (change in slope). Calendar
month (as a fixed effect) and a second order autoregressive function were included to account
for seasonality.
Lastly, the estimated practice-specific parameter for each of the random effects was examined to
classify practices according to whether their change in level and change in slope parameters represented
a significant increase or decrease (i.e., if the estimate’s 95% confidence interval excluded zero). Practice
characteristics were examined as predictors of decreases in level or slope using multivariate logistic
regression. Characteristics were included as standardised variables (i.e., rescaled to a mean of zero
and a standard deviation of one).
3. Results
This study included 7408 GP practices, which represents 98.4% of practices in England as of
September 2016. At baseline, included practices had a median of 6613 registered patients (interquartile
range (IQR) 4072–9919). The mean percentage of patients aged 65 years and over was 16.8% (SD 6.5),
and on average their patients were 49.9% female (SD 2.3). Practices had a median four GP FTEs (IQR
2–6.4). On average, 46.5% of GPs in a practice were female (SD 25.9) with 56.2% aged 45 years and
over (SD 28.4), while 25.5% of practices had a registrar.
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During September 2015, 88.9% of practices prescribed mirabegron and mirabegron comprised
a mean of 8.2% (SD 6.8) of OAB prescriptions (median 7.0%, IQR 3.6%–11.1%). This corresponded
to a mean of 76 OAB prescriptions, of which 6.2 were mirabegron. Variation between practices was
classified as very high and the median SCV did not change significantly (p = 0.11) in the six months
after the September 2015 DHPC (12.68) compared to the six months before (12.04). Among practices
with any mirabegron prescribing, standardised prescribing ratios in the six months before and after
September 2015 ranged from 0.44–14.1. Figure 1 is a dot plot which illustrates little change in variation
over the time period. Figure 2 shows a decile plot of mirabegron percentage, indicating the increasing
percentage over time, but little change in the distribution across deciles. Figure 3 shows the distribution
of practices by mean mirabegron percentage for rolling six-month periods relative to September 2015,
and the distribution was relatively symmetrical with respect to the Y-axis before and after the DHPC,
suggesting that between-practice variation remained relatively stable.
Segmented regression analysis indicates that before the DHPC, there was a trend of 0.294 (95%
confidence interval (CI), 0.287, 0.301) percentage points increase per month in the percentage of
OAB drugs prescribed as mirabegron (see Table 1 and Figure 4). There was no significant change in
percentage of mirabegron prescribing immediately after the DHPC (−0.023, 95% CI −0.105 to 0.058);
however, there was a small but significant reduction in trend (−0.036, 95% CI −0.049 to −0.023) after
the DHPC. Examining practice-level random effects, 1.8% of practices had an immediate decrease in
level of mirabegron prescribing, while 7.1% had a decrease in slope post-DHPC (see Table 2). Increases
in level and slope were observed in 1.9% and 4.5% of practices respectively. Estimated mirabegron
prescribing for sub-groups of practices with a decrease in level or slope is shown in Figure S1.
Table 1. Segmented regression analysis of mirabegron prescribing as a percentage of all overactive
bladder drug prescribing.
Parameters Adjusted Coefficient *(95% Confidence Interval) p Value
Monthly trend (slope) 0.294 (0.287 to 0.301) <0.001
Change in monthly trend post DHPC −0.036 (−0.049 to −0.023) <0.001
Level of prescribing at point of DHPC (intercept) 8.30 (8.16 to 8.44) <0.001
Change in level immediately post DHPC −0.023 (−0.105 to 0.058) 0.574
* Adjusted for calendar month. DHPC = direct healthcare professional communication.
Table 2. Number and percentage of practices by level and slope of mirabegron prescribing post direct
healthcare professional communication.
n (%)
Change in Level Change in Slope
Decrease a 133 (1.8) 529 (7.1)
No change 7133 (96.3) 6545 (88.4)
Increase b 142 (1.9) 334 (4.5)
a Decrease defined as a practice-level random effect for level/slope where the upper bound of the 95% confidence
interval is less than zero. b Increase defined as a practice-level random effect for level/slope where the lower bound
of the 95% confidence interval is greater than zero.
Table 3 shows practice characteristics associated with decreases in the level of prescribing and
slope. A higher number of registered patients, higher proportion of registered patients aged 65 years
and over, and deprivation were all associated with lower odds of an immediate decrease in the level of
mirabegron prescribing. Similarly, factors associated with lower odds of a decrease in slope included a
higher number of registered patients and deprivation.
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Figure 3. Distribution of practices by mean mirabegron percentage for rolling six-month periods relative to September 2015. Percentiles not shown where rolling mean
of mirabegron as a percentage of OAB prescribing is 0%.
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Table 3. Practices characteristics associated with a decrease in level of mirabegron prescribing or slope post DHPC.
Outcome of a Decrease in Level a Outcome of a Decrease in Slope a
Adjusted Odds Ratio
(95% Confidence Interval) p Value
Adjusted Odds Ratio
(95% Confidence Interval) p Value
GP workforce characteristics
GP full time equivalents 0.93 (0.52 to 1.66) 0.811 0.83 (0.63 to 1.09) 0.177
Proportion of female GPs 1.10 (0.95 to 1.28) 0.189 1.05 (0.97 to 1.15) 0.238
Proportion of GPs aged 45 and over 1.10 (0.94 to 1.30) 0.236 1.04 (0.95 to 1.14) 0.344
Any registrars b 0.83 (0.60 to 1.16) 0.283 1.08 (0.95 to 1.23) 0.233
Patient characteristics
Number of registered patients 0.40 (0.24 to 0.67) <0.001 0.57 (0.45 to 0.73) <0.001
Proportion of female patients 0.90 (0.80 to 1.02) 0.091 0.97 (0.89 to 1.05) 0.464
Proportion of registered patients aged 65
and over 0.52 (0.36 to 0.75) 0.001 0.88 (0.74 to 1.06) 0.180
Other practice characteristics
Overall QOF score percentage c 0.91 (0.80 to 1.05) 0.188 0.97 (0.90 to 1.06) 0.525
Hypertension prevalence 1.07 (0.81 to 1.42) 0.619 0.90 (0.77 to 1.04) 0.154
Dementia prevalence 0.83 (0.53 to 1.31) 0.428 0.83 (0.67 to 1.04) 0.102
Index of multiple deprivation (deciles) 1.30 (1.07 to 1.59) 0.010 1.22 (1.10 to 1.35) <0.001
a Decrease defined as a practice-level random effect for level/slope where the upper bound of the 95% confidence interval is less than zero. b A registrar is a doctor who has completed
foundation training and is training in the specialty of general practice. c Quality and Outcomes Framework (QOF) score reflects a practice’s performance against a range of indicators to
describe best practice.
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4. Discussion
Variation in mirabegron prescribing was high and this did not change significantly following
a DHPC. At the beginning of the study period, mirabegron was a relatively new medicine to be
authorised, having been approved by the EMA in December 2012 and first prescribed on the English
market from March 2013. This may be one explanation for the high variation, as practices may adopt
prescribing of new products at different rates [16]. At the time of the DHPC, the vast majority of
practices were prescribing mirabegron. There was no immediate prescribing change post-DHPC, and
although the monthly growth in mirabegron prescriptions did slow, the magnitude of this change
was small. Our study could only evaluate aggregate practice-level prescribing and could not separate
prevalent and incident use. The decline in the monthly rate of increase in mirabegron could potentially
be attributable to reduced incident use, however any change in mirabegron prescribing among at-risk
patients may not have been detectable at the practice-level.
Practices with more registered patients and those in more deprived areas were less likely to have
a reduction in the level and trend in mirabegron prescribing. This suggests that some practices have a
greater capacity to review and amend prescribing if there are fewer patients or less deprivation, or
these practices may have fewer or no patients with uncontrolled hypertension and no reason to alter
prescribing. Deprivation and inequality are associated with more complex care need through higher
prevalence of multimorbidity and polypharmacy [17,18], and poorer health outcomes [19]. In line with
the inverse care law, those most in need of care due to inequalities are often least likely to receive it
due to reduced capacity of care providers because of the added complexity of care [20,21]. Similarly,
the more older patients registered at a practice, the less likely an immediate reduction in the level of
mirabegron prescribing. For practices with older patient populations, reluctance to switch to alternative
oral OAB drugs (which may have anticholinergic effects) may have contributed to continued growth
in mirabegron prescribing. Mirabegron was a second-line therapy in national guidelines at this time
and so many patients may already have not responded to or tolerated an alternative OAB drug. No
alternatives were recommended in the DHPC, which reflects the limited therapeutic options for OAB
available to prescribers caring for older patients, among whom the prevalence of hypertension is high.
Alternative medicines for OAB are antimuscarinic, and older adults are particularly susceptible to the
anticholinergic effects of such agents (3), and further risks identified in recent years include dementia
and cognitive decline [22]. However this evidence is primarily derived from observational research
which considers all OAB drugs together, whereas newer agents such as darifenacin may not carry this
effect [23]. It is also possible that a doctor and patient for whom mirabegron may be cautioned could
decide that the benefits of continuing mirabegron for OAB may outweigh the potential cardiovascular
risks. This may be more likely given the relatively small number of cases which prompted the DHPC
and that further confirmatory studies have yet to be completed.
Although this appears to be the first study to evaluate variation in response to a DHPC regarding
a medication, previous research evaluating indicators of prescribing safety, high-risk prescribing,
and antipsychotic prescribing in UK general practice has found variation between practices was
similarly high [7,24,25]. Although several studies have evaluated the impact of DHPCs on a range of
outcomes, these have not assessed variation between healthcare professions [5,6,26,27]. Evaluating
the effectiveness of risk communication has become a focus area in recent years [28], as evidenced
by Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) Joint Action
which involves medicine regulators across Europe [29]. An understanding of variation in and the
determinants of response to regulatory safety communications among GP practices, and ideally
individual general practitioners, may allow for those that do not alter their prescribing to be provided
with tailored information and supports to promote safe medication use. There is evidence that there is
variation between countries in Europe in GP preferences for the format of safety communications [30].
Despite this, it appears that DHPCs represent the most common source of awareness of medicines’
safety issues among European GPs, pharmacists and cardiologists [31]. Previous research has indicated
that such communications have greater impact on non-specialist drugs and for safety issues with a risk
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of death and/or disability [8] however to date, the relationship between the characteristics of DHPCs
and variation in outcomes has not been evaluated. Further research should also evaluate additional
interventions to communicate safety information to healthcare professionals in cluster or stepped
wedge randomised controlled trials. The only such study to date examined the effect of an additional
email on the effectiveness of a DHPC in the Netherlands [32]. Depending on the timing and formats of
future DHPCs, this may present opportunities to evaluate the effectiveness of such communications in
natural experiments [6].
Systematic reviews illustrate that relatively few evaluations of regulatory actions have been
undertaken [5,33–35]. Regulatory actions relating to a range of therapeutic agents have been evaluated,
with antidepressants being the most commonly examined [33,35]. A substantial proportion of such
studies used study designs and analytical approaches which yield low quality evidence of the effects
of pharmacovigilance actions i.e., cross-sectional or before and after studies [33,34]. Unlike more
methodologically robust interrupted time series studies, these studies do not consider trends in
outcome and thus may overestimate the impact of an intervention of interest [10,36]. Therefore, the
methodological approach may have an impact on findings, as studies using more robust design tended
to report more conservative or mixed impacts of regulatory actions, like the present study [5,33,34].
Evaluating medication utilisation using prescribing or dispensing data is just one way of evaluating
such regulatory actions. Other quantitative evaluation could measure changes in adverse outcomes
relating to uncontrolled hypertension or cerebrovascular events in the case of mirabegron, or unintended
consequences such as inappropriate switching to another OAB drug. Recent proposals have outlined
a framework approach to evaluation, including quantitative and qualitative analysis of tradition
and social media uptake of the communications, qualitative research with healthcare professionals
and patients, as well as more traditional quantitative measures of process and outcomes [37].
Behaviour change and implementation science is a growing area of focus for regulatory bodies in
pharmacovigilance and risk minimisation programs [38]. This reflects that moving from awareness
of a regulatory safety communication to implementation in clinical practice is complex, with decay
at each step in the process [39]. Similarly, the use of complex interventions to support adoption of
regulatory safety warnings may increase their impact. For example, this could involve integrating
emerging safety communication within computer decision support systems in electronic health records
to flag warnings relevant to specific patients during clinical workflow. However, evidence on the
effectiveness of computer warnings is mixed, and requiring a reason to override messages may
improve effectiveness at the expense of potential alert fatigue [40]. Frameworks such as the adoption of
innovation (i.e., innovation, communication channels, time and adoption process, and social systems)
could be considered by regulatory agencies to optimise scale-up, spread, and uptake of regulatory
actions and communications [41].
This study has a number of strengths. It appears to be the first to assess the impact of the DHPC on
mirabegron’s cardiovascular risks on utilisation patterns of OAB drugs in a large primary care cohort.
We have also used the most robust method possible in evaluating temporal changes in prescribing.
A limitation of this study is the lack of patient-level data, which prevented analysis of mirabegron
prescribing among those patient groups affected referred to in the DHPC. It is possible that prescribers
may have reduced use of mirabegron in at-risk populations, which may not be detectable with a
concurrent rise in mirabegron prescribing to other patients in the practice. Lack of patient-level
data also precluded analysis of patient-level characteristics and their association with cessation of
mirabegron among prevalent at-risk patients. All of the characteristics examined were at the practice
level, with the exception of deprivation of the practice area. While this may indicate the deprivation
of the practice populations, there is potential for ecological bias in that registered patients may not
have been deprived despite the practice being located in a deprived area. We were also unable to
examine patient-level changes in prescribing to determine whether reductions in mirabegron use
were appropriately targeted at patients most at risk of cardiovascular harms. Inappropriate switching
to other OAB drugs in patients who already had a high anticholinergic burden as an unintended
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consequence could have resulted in increased net harm. Despite these limitations, this appears to be
the first study to evaluate variation between GP practices in response to a DHPC, which may be an
important consideration for future pharmacovigilance research.
5. Conclusions
While variation in healthcare has received much attention in recent decades, this has not extended
to variation in response to regulatory safety communications regarding medications. As medicine
regulators develop further strategies to improve the impact of DHPCs on clinical practice, heterogeneity
between prescribers in response to such warnings will become an important consideration.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/7/10/320/s1,
Figure S1: Estimated values for proportion of mirabegron prescribing without and with the direct healthcare
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All agents considered as overactive bladder drugs.
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